Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide Therapy.

ABSTRACT: Prostate cancer remains a prevalent and lethal malignancy across the globe. Despite ongoing advances in therapeutic approaches, these remain ineffective, and new treatments are drastically needed. Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy is a well-developed approach for prostate cancer treatment; however, current small molecule and antibody carriers for molecular radiotherapy each have drawbacks in their biodistribution and consequent side effects as highlighted in current clinical trials. To address this, we developed an approach to bioengineer the well clinically validated antibody carrier HuJ591 to yield an engineered, full-length antibody construct that achieves the beneficial fast pharmacokinetic profile of small molecule carriers alongside the enhanced

SUBMITTER: Fletcher NL 

PROVIDER: S-EPMC12670495 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature